ganfort
abbvie deutschland gmbh & co. kg - bimatoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmologice - reducerea presiunii intraoculare (pio) la pacienții cu glaucom cu unghi deschis sau hipertensiune oculară, care nu răspund insuficient la beta-blocantele topice sau la analogii de prostaglandină.
norvasc 10 mg
pfizer manufacturing deutschland gmbh - germania - amlodipinum - compr. - 10mg - bloc. selective canale calciu cu ef. preponderent vascular derivati dihidropiridinici
norvasc 5 mg
pfizer manufacturing deutschland gmbh - germania - amlodipinum - compr. - 5mg - bloc. selective canale calciu cu ef. preponderent vascular derivati dihidropiridinici
toujeo (previously optisulin)
sanofi-aventis deutschland gmbh - insulină glargină - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat la adulți, adolescenți și copii începând de la vârsta de 6 ani.
lantus
sanofi-aventis deutschland gmbh - insulină glargină - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat la adulți, adolescenți și copii cu vârsta de doi ani și peste.
accupro 10 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
accupro 20 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 20mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
accupro 5 mg
pfizer manufacturing deutschland gmbh - germania - quinaprilum - compr. film. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
aluvia comprimate filmate 200 mg + 50 mg
abbvie biopharmaceuticals gmbh - lopinavirum + ritonavirum - comprimate filmate - 200 mg + 50 mg